ACE-083 is a locally acting, follistatin-based therapeutic protein that binds myostatin and other regulators of muscle; in a first-in-human study, injections into a single leg muscle of healthy postmenopausal women increased that muscle's volume by up to 14.5% without changing mean muscle strength.
emerging — human data exists, and it is thin or contested
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
created page created as 'ACE-083' with aliases modified follistatin-Fc, FST(modified)-IgG2 Fc fusion, locally-acting follistatin trap · 2026-09-27 12:04 · somebody
kind set kind set to protein: palette r2 · 2026-09-27 12:04 · somebody
identity withheld identity not published: PubChem gave no record that proves it is this substance · 2026-09-27 12:04 · somebody
fact added summary: ACE-083 is a locally acting, follistatin-based therapeutic protein that binds myostatin and other regulators of muscle; · 2026-09-27 12:04 · somebody
fact added summary: In a randomized phase 2 study in facioscapulohumeral muscular dystrophy, injected biceps and tibialis anterior muscles g · 2026-09-27 12:04 · somebody
citation added pmid 29486514 cited as emerging: Locally injected ACE-083 increased targeted muscle volume in healthy volunteers without a mean stren · 2026-09-27 12:04 · somebody
citation added pmid 35428982 cited as emerging: ACE-083 increased muscle volume in FSHD without consistent functional improvement · 2026-09-27 12:04 · somebody
question added Has any study of ACE-083 shown a functional benefit, not only a gain in muscle volume? · 2026-09-27 12:04 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.